Research & Clinical Trials

Marion Bloch Neuroscience Institute

Research & Clinical Trials

Saint Luke’s Marion Bloch Neuroscience Institute features a strong clinical research program to ensure that patients receive the most effective and innovative treatment options.

With more than 140 patients currently enrolled in our 43 new or continued clinical research trials, we’re studying new therapies for:

  • Stroke intervention
  • Neuroprotection
  • Brain tumors
  • Alzheimer’s disease
  • Multiple sclerosis
  • Epilepsy
  • Hearing restoration

Since testing intravenous tPA, the clot-busting drug used to reverse strokes, in the early 1990s, Saint Luke’s Stroke Team has been involved in every major stroke intervention research trial. Early participation in trials testing mechanical devices to retrieve clots led to our extensive experience in clot retrieval and made us leaders in acute stroke treatment.

Saint Luke’s recently partnered with GE’s healthymagination initiative and submitted stroke data for detailed analysis by Oxford Analytica, an independent data analysis firm. The process included comparing our stroke treatment outcomes to those at hundreds of hospitals across the United States. Saint Luke’s stroke treatment outcomes in several categories were found to be significantly better than other hospitals. As a result, GE named Saint Luke’s the first healthymagination Stroke Solution Site in the world.